Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QRL-101 multiple ascending dose study in healthy participants
NL-OMON59837Phase 1Completed
- Sponsor
- QurAlis
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing QRL-101 multiple ascending dose with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Jun 2024; status: completed.
02
Drugs
QRL-101
Beyond the preview
Go deeper on NL-OMON59837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59837.